- What other names is Immortelle known by?
- What is Immortelle?
- How does Immortelle work?
- Are there safety concerns?
- Dosing considerations for Immortelle.
People take immortelle for liver and gallbladder disorders, including gallstones with accompanying cramps. It is also used to treat upset stomach (dyspepsia), loss of appetite, and fluid retention; to stimulate bile flow; and to fight germs.
Be careful not to confuse immortelle with sandy everlasting (Helichrysum angustifolium) or with immortal (Asclepias asperula).
Insufficient Evidence to Rate Effectiveness for...
- Gallstones and other gallbladder problems.
- Liver disorders.
- Upset stomach (dyspepsia) .
- Loss of appetite.
- Stimulating bile flow.
- Fighting bacteria.
- Other conditions.
Quick GuideVitamin D Deficiency: How Much Vitamin D Is Enough?
Special Precautions & Warnings:Pregnancy and breast-feeding: Not enough is known about the use of immortelle during pregnancy and breast-feeding. Stay on the safe side and avoid use.
Gallstones: Immortelle may cause colic (stomach cramps) in people with gallstones.
Blocked bile duct: Don't use immortelle if you have a blocked bile duct, because immortelle might stimulate the flow of bile.
Allergy to ragweed, daisies, and related plants: Immortelle may cause an allergic reaction in people who are sensitive to the Asteraceae/Compositae plant family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many others. If you have allergies, be sure to check with your healthcare provider before taking immortelle.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Last Editorial Review: 3/29/2011